Hoese & Co’s Novo Nordisk NVO Stock Holding History

Hoese & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-500	Closed	-$34.5K	–	141
2025 Q2	$34.5K	Hold	500	–	–	0.03%	114
2025 Q1	$34.7K	Hold	500	–	–	0.03%	85
2024 Q4	$43K	Hold	500	–	–	0.04%	76
2024 Q3	$59.5K	Hold	500	–	–	0.05%	65
2024 Q2	$67.6K	Hold	500	–	–	0.06%	51
2024 Q1	$59.9K	Hold	500	–	–	0.05%	59
2023 Q4	$50.9K	Hold	500	–	–	0.05%	63
2023 Q3	$45.5K	Hold	500	–	–	0.05%	70
2023 Q2	$40.5K	Hold	500	–	–	0.04%	81
2023 Q1	$35.2K	Hold	500	–	–	0.04%	80
2022 Q4	$31K	Hold	500	–	–	0.03%	91
2022 Q3	$25K	Hold	500	–	–	0.03%	96
2022 Q2	$28K	Hold	500	–	–	0.03%	95
2022 Q1	$28K	Hold	500	–	–	0.03%	103
2021 Q4	$28K	Hold	500	–	–	0.03%	105
2021 Q3	$24K	Hold	500	–	–	0.03%	107
2021 Q2	$21K	Buy	+500	New	+$19.4K	0.02%	123

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hoese & Co's NVO Position: Q3 2025 in Review

Hoese & Co sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 500 shares — an estimated $34.5K sold.

Hoese & Co first reported a position in NVO in Q2 2021 and held it in 17 quarters. The position peaked at $67.6K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Hoese & Co reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Hoese & Co sold 500 Novo Nordisk shares in Q3 2025, an estimated $34.5K.
Hoese & Co first reported a position in Novo Nordisk in Q2 2021 and held it in 17 quarters.
Hoese & Co's Novo Nordisk position peaked at $67.6K in Q2 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Hoese & Co's 13F filing for Q3 2025, filed 16 Oct 2025.